Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

Background: Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non-invasive Angulo NAFLD fibrosis score (FS) in an i...

Full description

Bibliographic Details
Main Authors: Peter P. Toth, Gregory G. Schwartz, Stephen J. Nicholls, Aziz Khan, Michael Szarek, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Ken Lebioda, Norman C.W. Wong, Michael Sweeney, Kausik K. Ray
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:American Journal of Preventive Cardiology
Subjects:
Apabetalone
Cardiovascular events
Fibrosis
Nonalcoholic fatty liver disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2666667722000563

Similar Items

Similar Items